Trials / Completed
CompletedNCT00439647
Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis
A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,199 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Male
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoledronic acid 5 mg iv | Zoledronic acid 5 mg iv given once a year. |
| DRUG | Placebo | Placebo intravenous (i.v.) once a year |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2007-02-23
- Last updated
- 2017-04-21
- Results posted
- 2011-11-16
Locations
128 sites across 23 countries: Argentina, Australia, Austria, Belgium, Brazil, Czechia, Denmark, Finland, Germany, Hungary, Iceland, Italy, Norway, Poland, Portugal, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00439647. Inclusion in this directory is not an endorsement.